According to a recent article published in Current Opinion in Endocrinology, Diabetes, and Obesity by CM Schooling titled “Testosterone and cardiovascular disease.”,  there is a clear link between use of testosterone supplements such as AndroGel and increased risk for heart attack.

Schooling (2014) writes, “Use of testosterone among men is increasing rapidly. Low

In 2010, a study was published in The New England Journal of Medicine titled “Adverse events associated with testosterone administration.” by S. Basaria and a team of researchers, aiming to further clarify adverse events associated with testosterone therapy.  Currently, testosterone therapy is provided in the treatment of “Low-T” and other ailments, many in

In the April, 2013 edition of BMC Medicine, L. Xu et al. published the results of a study titled “Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.”.  This study sought to assess the relative safety of testosterone therapy with respect to adverse cardiac events.  

The alpha-male. It’s a term traditionally used to describe an individual male mammal that is considered to hold the highest social standing in his community. Typically, an animal rises to alpha-male status by exhibiting signs of masculinity, confidence, and aggression to his peers. In acknowledgement of the alpha’s strength and leadership role, other members of

As lawsuits concerning the testosterone therapy drug AndroGel have recently been filed, a great deal of information has come to light concerning the marketing of that product.

Here is an excerpt from one of the current AndroGel lawsuits:

“In 2000, when the FDA approved AndroGel, the company announced that the market was ‘four to five

WARNING: Research shows AndroGel (AbbVie, Inc., Abbott Laboratories, Inc.) is overprescribed and can lead to “serious medical problems, including life threatening cardiac events, strokes, and thrombolytic events.”

AndroGel is a topically-applied gel containing testosterone at concentrations of either 1% or 1.62% used by patients suffering from hypogonadism, or “low-testosterone”.  While this